Cellular vimentin content regulates the protein level of hepatitis C virus core protein and the hepatitis C virus production in cultured cells  by Nitahara-Kasahara, Yuko et al.
Virology 383 (2009) 319–327
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roCellular vimentin content regulates the protein level of hepatitis C virus core protein
and the hepatitis C virus production in cultured cells
Yuko Nitahara-Kasahara a,1, Masayoshi Fukasawa a,⁎, Fumiko Shinkai-Ouchi a, Shigeko Sato a,
Tetsuro Suzuki b, Kyoko Murakami b, Takaji Wakita b, Kentaro Hanada a,
Tatsuo Miyamura c, Masahiro Nishijima a,d
a Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo 162-8640, Japan
b Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan
c National Institute of Infectious Diseases, Tokyo 162-8640, Japan
d National Institute of Health Sciences, Tokyo 158-8501, Japan⁎ Corresponding author. Fax: +81 3 5285 1157.
E-mail address: fuka@nih.go.jp (M. Fukasawa).
1 Present address: National Institute of Neuroscience
and Psychiatry, Tokyo 187-8502, Japan.
0042-6822/$ – see front matter © 2008 Published by E
doi:10.1016/j.virol.2008.10.009a b s t r a c ta r t i c l e i n f oArticle history: Hepatitis C virus (HCV) core
Received 14 August 2008
Returned to author for revision
3 September 2008
Accepted 6 October 2008




Vimentinprotein is essential for virus particle formation. Using HCV core-expressing and
non-expressing Huh7 cell lines, Uc39-6 and Uc321, respectively, we performed comparative proteomic studies
of proteins in the 0.5% Triton X-100-insoluble fractions of cells, and found that core-expressing Uc39-6 cells
had much lower vimentin content than Uc321 cells. In experiments using vimentin-overexpressing and
vimentin-knocked-down cells, we demonstrated that core protein levels were affected by cellular vimentin
content.When vimentin expressionwas knocked-down, therewas no difference inmRNA level of core protein;
but proteasome-dependent degradation of the core protein was strongly reduced. These ﬁndings suggest that
the turnover rate of core protein is regulated by cellular vimentin content. HCV productionwas also affected by
cellular vimentin content. Ourﬁndings together suggest thatmodulation of hepatic vimentin expressionmight
enable the control of HCV production.
© 2008 Published by Elsevier Inc.IntroductionHepatitis C virus (HCV) is a major causative agent of chronic
hepatitis (Choo et al., 1989; Kuo et al., 1989). Persistent HCV infection,
which develops in at least 70% of infected patients, is strongly
correlated with the development of severe liver diseases such as
ﬁbrosis, steatosis, cirrhosis, and hepatocellular carcinomas (HCC).
Since more than 170million people in theworld are currently infected
with HCV (Choo et al., 1989) and there is no treatment completely
effective in curing HCV, HCV infection is one of the most important
global public health issues. Understanding of the life cycle of HCV and
the mechanism by which HCV induces serious liver diseases is crucial
for the development of novel anti-HCV strategies.
HCV is anRNAvirus of the Flaviviridae family andpossesses a single-
stranded, positive-sense RNA genome of ∼9.6 kb (Bartenschlager and
Lohmann, 2000). The HCV RNA genome encodes a polyprotein of
∼3000 amino acids that is processed by host and viral proteases into 10
individual components including 4 structural and 6 nonstructural
proteins (reviewed by Reed and Rice, 2000). HCV core protein is crucial
for virus particle production as the structural component of the viral
nucleocapsid and as a unit required for formation of the active HCV, National Center of Neurology
lsevier Inc.replication/assembly complex in host cells (Boulant et al., 2007;
Miyanari et al., 2007). In addition, the core protein plays pivotal roles
in the pathogenesis of HCV infection, as suggested by the ﬁnding that
transgenic mice expressing core protein in the liver tend to develop
liver steatosis with subsequent HCC (Moriya et al., 1998; Moriya et al.,
1997). A large number of studies have revealed that a variety of host
proteins interact with the core protein (Suzuki et al., 2007). Although
these interactions can markedly affect various biological functions in
host cells, it is not clearly known yet which interactions andmolecules
play roles in HCV production or its pathogenicity. Recent exhaustive
gene-silencing analyses of host factors using RNAi demonstrated that
RNA helicase DDX3, one of the proteins that interacts with the core, is
required for HCV RNA replication as well as HCV production (Ariumi
et al., 2007; Randall et al., 2007).
In host hepatic cells, HCV core protein is distributed preferentially
in the detergent-resistant fractions (Matto et al., 2004), and HCV
RNA replication also occurs on detergent-resistant membranes
(Aizaki et al., 2004; Shi et al., 2003), suggesting that host factors in
the detergent-resistant fractions play roles in core protein functions.
In this study, we focused on HCV core protein and the detergent-
insoluble proteins of host cells, and performed comparative targeted
proteomic analysis of the detergent-insoluble proteins in HCV core-
expressing and non-expressing hepatic cells. We identiﬁed vimentin
as a protein the amount of which was reduced in core-expressing
cell lines, and demonstrated that cellular vimentin content affects
levels of HCV core protein through the proteasome-mediated protein
320 Y. Nitahara-Kasahara et al. / Virology 383 (2009) 319–327degradation system. Since cellular vimentin levels ultimately affected
HCV production, vimentin may be a novel target for strategies of
anti-HCV treatment.
Results
Proteomic analysis of detergent-insoluble fractions (DISFs) by
second-dimensional polyacrylamide gel electrophoresis
(2D-PAGE)/MALDI-QIT-TOF MS
DISFs and detergent-soluble fractions (DSFs) were prepared from
HCV core-expressing Uc39-6 and non-expressing Uc321 cells by a
sucrose density gradient ultracentrifugation method as described in
Materials and methods. Proteins in the DISFs and DSFs were analyzed
by immunoblotting with antibodies to HCV core protein and various
organelle markers (Fig. 1A). A signiﬁcant amount of HCV core protein
(∼70%) was distributed in the DISF of Uc39-6 cells. Nuclear proteinsFig. 1. Immunoblot and 2D-PAGE analysis of DISFs. (A) Total cell lysate fractions (5 μg of prote
non-expressing Uc321 cells were analyzed by immunoblotting with antibodies to HCV core
DISFs of Uc321 and Uc39-6 cells. Proteins (150 μg) were separated by IEF (pH 4–7), followed b
as cytoskeletal proteins, are marked: 1, vimentin; 2, cytokeratin 8; 3, cytokeratin 18; 4, actisuch as laminA/C and laminB were concentrated only in the DISFs of
both types of cells, whereas other organelle proteins such as annexin II
(plasma membrane), fatty acid synthase (cytosol), prohibitin (mito-
chondria), and calnexin (endoplasmic reticulum) were detected in the
DSFs but not DISFs (Fig. 1A), suggesting that the DISFs in both types of
cells contain minor (∼15%) discrete populations of cellular proteins.
Next, we performed 2D-PAGE analysis of the DISFs in Uc321 and Uc39-
6 cells. Proteins in the DISFs were separated by isoelectric focusing
(IEF) (pH 4–7) and 12% sodium dodecyl sulfate (SDS)-PAGE, and
visualized by SYPRO-Ruby staining (Fig. 1B). Intensity of each spot in
2-D images was compared between Uc321 and Uc39-6 cells. The most
difference in DISF proteins between Uc321 and Uc39-6 cells (the
Uc39-6/Uc321 ratios of intensity normalized with actin: 10.8–28.0)
was detected in the spots numbered as 1 in Fig. 1B (MW∼57 kDa,
pI∼4.7), in which vimentin alone was identiﬁed by mass spectro-
metric analysis. We therefore focused on the relationship between
cellular vimentin and core protein in further investigations.in), DSFs (50 μg of protein), and DISFs (5 μg of protein) from core-expressing Uc39-6 and
protein and various organelle markers as indicated. (B) 2D-PAGE analysis of proteins in
y SDS-PAGE on a 12% gel. The gels were stained with SYPRO-Ruby. Major spots, identiﬁed
n. ⁎: a non-speciﬁc spot.
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To conﬁrm the reduction of vimentin levels in DISFs of HCV core-
expressing Uc39-6 cells, immunoblot analysis was performed using
anti-vimentin antibody. Uc39-6 cells exhibited lower vimentin
contents not only in DISF but also the total cell lysate fraction
compared with control Uc321 cells (Fig. 2A). Similar results were
obtained in the cell lysate fraction of another independent clone of an
HCV core-expressing Huh7 cell line, Uc39-2 (Fig. 2B). Furthermore, a
core-expressing hepatic HepG2 cell line, Hep39, also had lower
vimentin content than a control cell line, Hepswx (Fig. 2C). These
ﬁndings exclude the possibility that the reduction of vimentin levels
in core-expressing cell lines is a clone- or cell-speciﬁc event.
Consistent with these ﬁndings, levels of vimentin mRNA in Uc39-2
and Uc39-6 cells were also lower than that in Uc321 cells (data not
shown). Taken together, these ﬁndings demonstratemarked reduction
of vimentin expression in HCV core-expressing cell lines.
Cellular vimentin content affects the protein level of HCV core protein
To investigate the relationship between HCV core protein and
vimentin, we examined the effect of cellular vimentin content on level
of HCV core protein. When the expression of vimentin or control
hypoxanthine guanine phosphoribosyltransferase 1 (HPRT) wasFig. 2. Immunoblot analysis of vimentin in HCV core-expressing cell lines. Cell lysate
fractions and DISFs from various cell lines were analyzed by immunoblotting with
antibodies to vimentin, HCV core protein, and β-actin as indicated: cell lysate fractions
and DISFs from Uc321 and Uc39-6 cells in (A), cell lysate fractions from Uc321, Uc39-2,
and Uc39-6 cells in (B), and cell lysate fractions and DISFs fromHepswx and Hep39 cells
in (C). Amounts of protein loaded were 18 μg in (A) and (B), and 5 μg in (C).knocked down in Uc39-6 cells by siRNA treatment, the protein level
of HCV core protein in vimentin-knocked-down cells was signiﬁcantly
higher than those in siRNA-untreated and HPRT-knocked-down cells
(Fig. 3A). On the other hand, cellular mRNA levels of HCV core protein,
corrected for β-actin mRNA content, did not differ substantially
among these types of cells (Table 1). These ﬁndings revealed that post-
translational steps were involved in the increase of HCV core protein
level in vimentin-knocked-down cells. Next, we established a
vimentin-overexpressing Huh7 cell line, Huh7/vimentin, and com-
pared the level of the core protein in Huh7/vimentin cells with that in
control Huh7/hygro cells after transient expression of the core protein
with pcEF39neo vector. After 9-day culture with G418 selection, the
viabilities of the two types of cells were similar, though the level of
expression of the core protein in Huh7/vimentin was signiﬁcantly
lower than that in Huh7/hygro cells (Fig. 3B). These ﬁndings
demonstrated that level of HCV core protein was inversely correlated
with cellular vimentin content, and thus strongly suggested that it was
affected by cellular vimentin content.
We further attempted to verify these effects of vimentin using the
vimentin-null cell line 1HF5 and the vimentin-expressing control cell
line 2CB5, derived from human adrenal carcinoma SW13 cells (Sarria
et al., 1990). When 1HF5 and 2CB5 cells were transfected with the core
expression vector pcEF39neo and cultured with G418 selection, the
viabilities of the two types of cells were similar, though the level of
expression of the core protein in 1HF5 cells wasmuch higher than that
in 2CB5 cells (Fig. 3C), consistent with the results in Figs. 3A, B. An
exogenously vimentin-expressing 1HF5 cell line carrying pcDNA3.1/
Hygro/vimentin, 1HF5/vimentin, and a control vimentin-null cell line
carrying pcDNA3.1/Hygro, 1HF5/hygro, were then established, and
transfected with the green ﬂuorescent protein (GFP)-expressing
pcDNA3.1/EGFP vector, the core-coding pcEF39neo vector, or the
control pcFE321swxneo vector. After selection under G418 for 9 days,
the viabilities of these transfected cells were nearly the same. The
levels of expression of GFP were similar in 1HF5/hygro and 1HF5/
vimentin cells, while the core protein level in 1HF5/vimentin cells was
signiﬁcantly lower than that in 1HF5/hygro cells (Fig. 3D), consistent
with the results in Fig. 3B.
These ﬁndings together indicate that cellular vimentin content
regulates the level of HCV core protein in post-translational fashion.
Vimentin is involved in proteasomal degradation of core proteins in cells
HCV core proteins are known to be preferentially degraded by the
proteasome-dependent pathway (Suzuki et al., 2001). To determine
whether cellular vimentin content affects proteasome-dependent
degradation of the core protein, we examined the effects of the
proteasome inhibitor MG132 on core protein levels in vimentin-
knocked-down cells. After Huh7 cells transfectedwith pCAG/Flag-core
(Huh7/Flag-core cells) had been treated with MG132 for 16 h, cellular
accumulation of core protein was analyzed by immunoblot (Fig. 4;
lanes 3 vs 4), which indicated substantial proteasomal degradation of
the core proteins in cultured cells, as described previously (Hope and
McLauchlan, 2000; McLauchlan et al., 2002; Suzuki et al., 2001).
Huh7/Flag-core cells transfected with control and HPRT siRNA
duplexes exhibited similar increases in core protein levels by
treatment with MG132 (Fig. 4; lanes 5 vs 6, and 9 vs 10). On the
other hand, vimentin-knocked-down Huh7/Flag-core cells that were
transfected with vimentin siRNA duplexes exhibited higher content of
core protein (lane 7) than the other siRNA-treated cells (lanes 5 and 9),
and MG132 treatment resulted in no signiﬁcant difference in core
protein levels in vimentin-knocked-down cells (lanes 7 and 8),
indicating that proteasomal degradation of core proteins was
markedly inhibited in the vimentin-knocked-down cells. These
observations strongly suggested that vimentin plays an important
role in the proteasome-mediated proteolytic pathway of the HCV core
protein.
Fig. 3. Effects of cellular vimentin content on the level of expression of HCV core protein. Cellular level of expression of vimentin, HCV core protein, HPRT, β-actin, and GFP were
analyzed by immunoblotting of total cell lysates (40 μg of protein) from various cells using speciﬁc antibodies. (A) Uc39-6 cells were transfected twice with a 2-day interval without
(−) or with vimentin or control HPRT siRNA duplexes. Four days after the ﬁrst transfection, cell lysates were collected and analyzed. (B) Huh7/hygro and Huh7/vimentin cells were
transfected with the core protein-expression vector pcEF39neo, and selected under 1 mg/ml of G418 for 9 days. (C) The 2CB5 (vimentin+) and 1HF5 (vimentin−) lines of SW13 cells
were transfected with pcEF39neo, and selected under 1 mg/ml of G418 for a week, followed by additional 2-week culture in normal culture medium. (D) 1HF5/hygro and 1HF5/
vimentin cells were transfected with pcDNA3.1/EGFP (GFP), pcFE321swxneo (321), or pcEF39neo (39), and selected under 1 mg/ml of G418 for 9 days.
Table 1
mRNA levels of HCV core protein and β-actin in vimentin-knocked-down Uc39-6 cells
siRNA
– HPRT vimentin
HCV core (×104 copies/μg total RNA) 2.9±0.3 1.7±0.1 3.0±0.2
β-actin (×107 copies/μg total RNA) 3.0±0.1 1.4±0.1 2.3±0.0
HCV core/β-actina 1 1.3 1.3
Total RNA was isolated from Uc39-6 cells that had been treated twice with a 2-day
interval with HPRT siRNA duplexes, with vimentin siRNA duplexes or without (−) either
of them, and cultured for 4 days. mRNA levels of HCV core protein and β-actin (a control
housekeeping gene) were determined by quantitative real-time PCR. Values are the
mean±SD for three determinations.
a Numbers represent the relative amounts of HCV core protein mRNA normalized to
β-actin level.
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examined the protein levels of p53, one of the endogeneous host
proteins the degradation of which is mainly regulated by proteasomal
system (Morimoto et al., 2008). The pattern of p53 protein levels was
very similar to that of core protein levels (Fig. 4), suggesting that the
vimentin-dependent proteasomal degradation is not speciﬁc for the
viral core protein. Vimentin-dependent proteasomal degradation
systemmight be generally important for the turnover of endogeneous
cellular proteins as well as the viral core protein.
Cellular vimentin contents affect HCV production
Since the level of expression of HCV core protein was affected by
cellular vimentin content, we examined whether HCV production was
also affected by cellular vimentin content. Infectious HCV (JFH1 strain)
particles were used for the following infection assays. HCV production
activity was determined by quantiﬁcation of HCV core protein levels in
the infected cells and culture supernatants. We ﬁrst tested the effect of
vimentin knockdownonHCVproduction. Examination ofHCV-infected
Huh7 cells treated with vimentin siRNA revealed higher amounts of
HCV core protein in both cells and culturemedium than examination of
non-treated and control HPRT siRNA-treated cells (Fig. 5A). To examine
whether the core protein levels in the cell-cultured media reﬂect the
content of infectious HCV particles in them, Huh7 cells were treated
with cell-cultured medium containing equal amounts (1.4 fmol) of the
core protein collected from each type of cell described in Fig. 5A, and
cellular levels of production of the core protein were determined by
immunoblot analysis. They were nearly the same among the cells
treated with each culture medium (Fig. 5B). These ﬁndings indicated
that reduction of vimentin expression inHuh7 cells leads tomore active
HCV production and enhanced release to the supernatant.We next examined the effects of vimentin overexpression on HCV
production. When vimentin-overexpressing Huh7/vimentin and con-
trol Huh7/hygro cells were infected with HCV particles, Huh7/
vimentin cells exhibited lower amounts of intracellular and extra-
cellular HCV core protein than Huh7/hygro cells (Fig. 5C). Consistent
with the results in Fig. 5A, these ﬁndings suggested that higher
expression of vimentin in host cells resulted in lower HCV production.
We also examined the effect of vimentin knockdown on HCV RNA
replication using a JFH1-subgenomic replicon (Fig. 5D). There were no
signiﬁcant differences in replication activities between vimentin-
knocked-down cells and the other control cells. These ﬁndings
indicated that cellular level of vimentin has no effects on HCV non-
structural proteins which serve as a unit of RNA replication machinery
of HCV. Collectively, these results demonstrated that HCV production
activity but not HCV-RNA replication was inversely correlated with
cellular vimentin content.
Fig. 4. Effects of the proteasome inhibitor MG132 on level of expression of HCV core protein in Huh7 cells. siRNA duplexes of control, HPRT, or vimentin, together with the core
protein-expression vector pCAG/Flag-core, were transfected into Huh7 cells. After 2 days, transfection of these siRNAs was repeated. Cells were further cultured for 2 days and treated
with (+) or without (−) MG132 (50 μM) for 16 h. Equivalent amounts of cell lysates were analyzed by immunoblotting with antibodies to vimentin, HPRT, core protein, p53, and
GAPDH.
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cells after HCV infection was observed by immunoﬂuorescence
microscopy (Fig. 5E), and the ﬂuorescent intensity of vimentin in
core-positive and core-negative Huh7 cells under HCV-infected
conditions was determined (Fig. 5F). HCV-infected cells stained with
the core-speciﬁc antibody always had lower vimentin content (Figs. 5E,
F). Moreover, as shown in Fig. 5F, HCV core-negative cells exhibited
more variable vimentin levels, whereas the core-positive cells had
vimentin levels within a narrow range. These observations, which
showed that a Huh7 cell population with lower vimentin content can
preferentially produce HCV, were consistent with the results shown in
Figs. 5A, C.
Finally, we examined the effects of MG132 on HCV core protein
levels in HCV-infected cells in which vimentin was knocked-down or
overexpressed. In the presence of MG132, non-treated and control
HPRT siRNA-treated cells showed the signiﬁcant increase of cellular
HCV core protein levels, whereas vimentin-knocked-down cells did
not (Fig. 5G). These results were consistent with those using HCV
core-expressing cells (Fig. 4). HCV core content in vimentin-
overexpressing Huh7/vimentin cells was lower than that in control
Huh7/hygro cells, but after MG132 treatment Huh7/vimentin and
Huh7/hygro cells showed the similar HCV core protein levels (Fig.
5H). Taken together, these results demonstrated the signiﬁcant
involvement of vimentin in proteasome-dependent degradation of
HCV core protein in HCV-infected cells (Figs. 5G, H), as well as in
HCV core-expressing cells (Fig. 4).
Discussion
By comparative proteomic analysis of the detergent-insoluble
proteins in HCV core-expressing and non-expressing Huh7 cell lines,
vimentin, an intermediate ﬁlament protein, was identiﬁed as the
protein with the most dramatic reduction in level in the detergent-
insoluble fraction of HCV core-expressing Uc39-6 cells (Figs.1B and 2).
On the other hand, there were no signiﬁcant differences in the
amounts of other major proteins including cytoskeletal components
such as actin and cytokeratin 8/18 in the detergent-insoluble fractions
between the core-expressing and non-expressing cells (Fig. 1B). These
ﬁndings, together with similar results for other core-expressing cells
(Fig. 2), suggested the existence of a speciﬁc relationship between the
core protein and cellular vimentin. Consistent with these ﬁndings,immunoﬂuorescence microscopic analysis of core-expressing cells
(data not shown) and HCV-infected cells (Figs. 5E, F) showed that cells
with intrinsic lower amount of vimentin are more permissive for
higher HCV core protein content.
Knockdown of vimentin expression by siRNA treatment resulted in
an increase in HCV core protein levels (Fig. 3A), while overexpression of
vimentin reduced core protein contents (Fig. 3B). Similar results were
obtained in the experiments using the vimentin-null cell line 1HF5
derived from SW13 cells (Figs. 3C and D). On the other hand, transient
knockdown and overexpression of the core proteins in Uc39-6 and
Huh7 cells, respectively, did not result in differences in cellular
vimentin content (data not shown). These ﬁndings indicated that
cellular vimentin level affects the level of expression of the core protein
but not vice versa. Although transient expression of the core protein did
not affect cellular vimentin content, why do various stable cell lines
expressing the core protein have lower vimentin level? Since it was
very hard to establish the cells stably expressing the core protein, we
speculate that only the minor cell population innately having lower
vimentin content was able to maintain the substantial core expression
levels and was therefore selected.
We next demonstrated that vimentin affects core protein levels in
post-translational fashion (Table 1) and is required for the proteaso-
mal degradation of core protein in core-expressing cells (Fig. 4) and
also in HCV-infected cells (Figs. 5G, H). Many studies with protea-
some inhibitors have shown that a major pathway of degradation of
core protein is mediated by the proteasomal system (Hope and
McLauchlan, 2000; McLauchlan et al., 2002; Moriishi et al., 2003;
Suzuki et al., 2001). PA28γ, a REG family proteasome activator also
known as REGγ and Ki antigen, which is located in the nucleus, was
shown to play an important role in the proteasomal degradation of
the core protein (Moriishi et al., 2003). It was recently reported that
the ubiquitin ligase E6AP, which is distributed in the perinuclear
cytoplasm and colocalized with the core protein, is also involved in
ubiquitylation and degradation of core protein (Shirakura et al.,
2007). Vimentin ﬁlaments extend from the nuclear membrane
toward the cell periphery. In addition, vimentin is known to
colocalize with ubiquitinated protein aggregates and form aggre-
somes when the capacity of the proteasome is exceeded (Johnston et
al., 1998). Pull-down assays against the core protein in core-
expressing Huh7 cells indicated that a minor portion of cellular
vimentin can interact with HCV core protein (data not shown), as
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cellular vimentin and the core protein on immunoﬂuorescence
microscopy also supported the existence of a minor but deﬁnite
association between them (data not shown). Based on these ﬁndings,
we speculate that vimentin plays a role in the transport of the core
protein to the nucleus, where it is then degraded, although further
biochemical studies will be needed to demonstrate this.
HCV core protein is distributedmainly in the ER and lipid droplets in
host cells (Barba et al.,1997), and theERmembrane associating the lipiddroplets with core protein has been recognized as a site important for
HCV production, particularly HCV RNA replication and virus particle
assembly (Boulant et al., 2007; Miyanari et al., 2007). Vimentin is also
closely associatedwith lipid droplets (Brasaemle et al., 2004; Lieber and
Evans, 1996; Schweitzer and Evans, 1998). Thus, in addition to its
degradative modulation of core protein, vimentin might also affect the
function of lipid droplets and consequently inhibit HCVproduction. The
effects of vimentin knock-downandoverexpression onHCVproduction
were actually stronger at the extracellular core protein level (secretion
325Y. Nitahara-Kasahara et al. / Virology 383 (2009) 319–327of the virus) than at the intracellular core protein level (Figs. 5A, C),
suggesting additional activity of vimentin in the processes of HCV
particle release.
Since the level of expression of vimentin in carcinomas is
correlated with parameters of malignant potential such as tumor
grade and tumor invasion, vimentin has been used as a marker of
malignant tumors (Bannasch et al., 1982). It has indeed been reported
that some HCV-infected patients with hepatocellular carcinoma
exhibited up-regulation of vimentin expression in tumor tissue (Kim
et al., 2003) although further statistical studies are required to clearly
demonstrate this. Tanaka et al. noted that in livers of HCV-infected
patients with hepatocelllular carcinoma the virus existed predomi-
nantly in non-cancerous tissue, at levels 10- to 100-fold higher than in
cancerous tissue (Tanaka et al., 2004). These observations in human
liver samples suggest that the reduction in HCV levels in hepatic
tumor can be explained by the increase of vimentin expression in
tumor, consistent with our ﬁndings for cultured cells.
In this study we demonstrated that cellular vimentin expression
enhanced the proteasomal degradation of core protein and eventually
restricted HCV production. Vimentin itself and sites of vimentin/core




Mouse monoclonal antibodies to annexin II, fatty acid synthase,
calnexin, lamin A/C, and GFP were purchased from BD Transduction
Laboratories. Mouse monoclonal antibodies to HCV core protein,
prohibitin, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were from Anogen, Lab Vision, and Abcam, respectively. Rabbit
polyclonal antibodies to vimentin, lamin B1, p53, and HPRT were
from Santa Cruz Biotechnology Inc., while those to actin were from
Biomedical Technologies Inc.
Plasmids
The mammalian expression vector of HCV core protein, pcEF39neo
(Ruggieri et al., 1997), and the empty vector pcEF321swxneo (Harada
et al., 1995) were described previously. The mammalian expression
vector of Flag-tagged HCV core protein, pCAG/Flag-core, and the
empty vector, pCAG, were described previously (Moriishi et al., 2003).
For construction of a mammalian expression vector of vimentin,
pcDNA3.1/Hygro/vimentin, vimentin fragment was ampliﬁed by PCR
using the reverse-transcribed cDNAs of Huh7 cells as a template. The
PCR primer pairs used were 5′-GCCATGTCCACCAGGTCCGTGTCC-3′ and
5′-TTATTATTCAAGGTCATCGTGATG-3′. The PCR products were inserted
into the EcoRV site of pBluescript SKII(+). pBluescript SK(+)/vimentin
was digested with Hind III and Xba I, and the vimentin fragment was
inserted into pcDNA3.1/Hygro (Invitrogen), which had been digestedFig. 5.HCV production in vimentin-knockdown and vimentin-overexpressing Huh7 cells. (A)
(including 8.0 fmol of core protein) for 6 h, and then treated twice with a 3-day interval with
HCV core protein per cell in cells (light gray bar) and culture medium (dark gray bar) were d
described above in (A). The concentration of HCV core protein in these samples of mediumw
medium containing 1.4 fmol of HCV core protein for 2 days, and harvested after 7-day incub
HCV core protein and β-actin. (C) Vimentin-overexpressing Huh7/vimentin and control Huh
HCV core protein per cell in cells (light gray bar) and culture medium (dark gray bar) were de
reporter gene were transfected without (−) or with siRNA duplexes of HPRT or vimentin
Immunoﬂuorescence microscopic analysis of HCV-infected Huh7 cells. After infection with
were then detected with speciﬁc antibodies. Nuclei (blue) were stained with DAPI. Two vie
50 μm in the right panel. (F) Under the HCV-infected conditions in panel E, ﬂuorescence inte
proﬁle analysis. n=40. Statistical signiﬁcance of differences in ﬂuorescence intensity of vime
showing pb10−8. (G) As in (A), Huh7 cells were incubated with HCV particles, and then treat
After 4.5-day culture, cells were treated with (+) or without (−) MG132 (50 μM) for 16 h. In eac
in MG132-untreated cells was determined. n=3. (H) Huh7/vimentin and Huh7/hygro cells i
(50 μM) for 16 h. The amounts of cellular core protein per cell were determined. n=3.with Hind III and Xba I. For construction of pcDNA3.1/EGFP, EGFP
fragment was prepared by digestion of pEGFP-N1 (Clontech Labora-
tories, Inc.) with Nhe I and Hind III and inserted into pcDNA3.1/Hygro,
which had been digested with Nhe I and Hind III. The subgenomic
replicon constructs, pSGR-JFH1/Luc (wild type) and pSGR-JFH1/Luc-
GND (GND mutation in the NS5B sequence), with the ﬁreﬂy luciferase
reporter gene were described previously (Kato et al., 2005).
Cell lines
All hepatic cells used in this study were plated on collagen-coated
dishes (Asahi Techno Glass, Japan). Human hepatic Huh7 and Huh7.5.1
cells were grown in normal culture medium [Dulbecco's modiﬁed
Eagle's medium (DMEM) (KOJIN BIO, Japan) supplemented with 10%
fetal bovine serum (FBS), 100 U/ml Penicillin G, and 100 mg/ml
streptomycin sulfate] containing 0.1 mM non-essential amino acids
(GIBCO) under a 5% CO2 atmosphere at 37 °C. We used human hepatic
cell lines constitutively expressing HCV core protein, including Hep39
from HepG2 cells (Harada et al., 1995; Ruggieri et al., 1997) and Uc39-2
and Uc39-6 from Huh7 cells (Fukasawa et al., 2006; Sato et al., 2006).
Huh7 and HepG2 cell lines carrying the empty vector, Hepswx and
Uc321, respectively, were used as a mock control. All of these stable
transfectants were maintained in normal culture medium containing
1 mg/ml G418 (Sigma). The human adrenal carcinoma cell line SW13,
the subtypes 2CB5 and 1HF5 of which do or do not express vimentin,
respectively (Sarria et al., 1990), was maintained in normal culture
medium. When the pcDNA3.1/EGFP vector was transfected into 2CB5
and 1HF5 cells, the percentage of GFP-positive cells was 56.3% and
53.6%, respectively, 2 days after transfection (n=3), indicating that there
was no difference in the transfection efﬁciency between these cells. To
establish vimentin-overexpressing cells, pcDNA3.1/Hygro/vimentin
was transfected into 1HF5 and Huh7 cells using FuGENE 6 transfection
regent (Roche). The vimentin-overexpressing Huh7 and 1HF5 cells
were selected under hygromycin for 2 weeks and cloned to obtain
Huh7/vimentin cells and 1HF5/vimentin cells, respectively. Huh7 and
1HF5 cells carrying the empty vector pcDNA/Hygro were also
established, as Huh7/hygro cells and 1HF5/hygro cells, respectively.
Preparation of DISFs
Conﬂuent monolayers of Uc321 and Uc39 cells in four culture
dishes (150 mm inner diameter) were harvested by trypsinization,
and 1.5×107 cells of each were pelleted by centrifugation (218 ×g for
5 min at 4 °C). After washing with PBS three times, each cell pellet was
resuspended in 1 ml of lysis buffer [10 mM HEPES-HCl, pH 7.5, 10 mM
NaCl, 140 mM KCl, 0.5 mM DTT, 0.5% Triton X-100 (Pierce
Biotechnology), 10 mM NaF, Complete™ EDTA-free (Roche)] (i.e. a
20% cell suspension). The cell suspension was lysed with a ball-
bearing homogenizer (Hope et al., 2002). The soluble fraction
(designated the detergent-soluble fraction, DSF) containing ∼85% of
the total cellular proteins was collected by centrifugation of the cellHuh7 cells (5×104 cells) in 48-well plates were incubated with or without HCV particles
out (−) or with siRNA duplexes of HPRT or vimentin. After 7-day culture, the amounts of
etermined. n=3. (B) Culture mediumwas collected at day 6 in the infection experiment
as adjusted to 2.7 fmol/ml with fresh medium. Cells were infected with these samples of
ation. Infectivity was analyzed by the immunoblotting of cell lysates with antibodies to
7/hygro cells infected with HCV were harvested after 7-day incubation. The amounts of
termined. (D) Huh7 cells harboring the HCV subgenomic replicon containing a luciferase
. After 2.5-day culture, luciferase activity in cell extracts was determined. n=3. (E)
HCV, Huh7 cells were cultured for 6 days. HCV core protein (green) and vimentin (red)
ws showing low and high magniﬁcations are displayed. Bars, 100 μm in the left panel;
nsity of vimentin in core-positive and core-negative Huh7 cells was determined by line
ntin between core-positive and core-negative cells was evaluated using Student's t test,
ed twice with a 2-day interval without (−) or with siRNA duplexes of HPRT or vimentin.
h culture condition, the ratio of HCV core protein level in theMG132-treated cells to that
nfected with HCV were cultured for 4 days and treated with (+) or without (−) MG132
326 Y. Nitahara-Kasahara et al. / Virology 383 (2009) 319–327lysate performed twice at 218 ×g for 5 min at 4 °C. The insoluble pellet
was suspended in 2 ml of lysis buffer containing 1.62 M sucrose and
then centrifuged at 10,000 ×g for 1 h at 4 °C. The pellet was
resuspended in 1 ml of lysis buffer containing 1.0 M sucrose and
layered over 2 ml of lysis buffer containing 2.0 M sucrose. After
centrifugation at 50,000 ×g for 2 h at 4 °C, the precipitated fraction
containing ∼15% of total cellular proteins was collected and
resuspended in lysis buffer containing 0.25 M sucrose at a concentra-
tion of 3 mg protein/ml (designated the detergent-insoluble fraction,
DISF). Each fraction was stored at −80 °C until use. The protein
concentrations in these preparations were determined with BCA
protein assay reagents (Pierce Biotechnology) using BSA as a standard.
2D-PAGE/MALDI-QIT-TOF MS analysis
The DISF (0.15 mg protein) of each cell line was cleaned using a
PlusOne™ 2-D Clean Up kit (GE Healthcare) and resuspended in
rehydration solution containing 9 M urea, 4% CHAPS, 65 mM
dithioerythritol, and 0.5% ampholyte. The ﬁrst-dimensional IEF was
performed with an Immobiline Dry Strip pH 4–7 according to the
manufacturer's instruction (GE Healthcare). The second-dimensional
electrophoresis was carried out on 12% SDS-polyacrylamide gel, and
the gel was stained with SYPRO-Ruby (Bio-Rad). Spot detection and
comparison in 2D images were accomplished with PDQuest™ 2-D
analysis software ver. 7.3 (Bio-Rad). The protein bands were excised
from the gel and subjected to in-gel trypsin digestion. The tryptic
peptide mixtures were analyzed by MALDI-QIT-TOF MS (AXIMA-QIT,
Shimazu Biotech, Japan) as described previously (Sato et al., 2006;
Shevchenko et al., 1996). Mascot software (Matrix Science) was used
for protein identiﬁcation.
Immunoblot analysis
The proteins were separated by electrophoresis in precast NuPAGE
10% or 12% Bis–Tris gels (Invitrogen), and then transferred to a
polyvinylidene diﬂuoride membrane. The membranes were blocked
overnight at 4 °C or for 60 min at room temperature in Tris-buffered
saline containing 0.1% Tween 20 and 5% skim milk. The blots were
probed with the ﬁrst antibodies at 1:1000 dilution for 60 min at room
temperature and then incubated with horseradish peroxidase (HRP)-
conjugated goat anti-rabbit IgG (Bio-Rad) or HRP-conjugated goat
anti-mouse IgG (GE Healthcare) at 1:2000 dilution for 45 min.
Detection of immunoreactive proteins was performed using an ECL
system (GE Healthcare).
Quantitative real-time PCR analysis
Cellular total RNAs were prepared with an RNeasy kit (Qiagen). The
total RNA fraction (1 μg) was processed directly to cDNA using a
Transcriptor First Strand cDNA Synthesis Kit (Roche). Of the total 20 μl
cDNA solution, an aliquot of 0.5–2 μl was used for each real-time PCR
assay. The PCR primers used for HCV core protein were: forward, 5′-
AGGAAGACTTCCGAGCG-3′, and reverse, 5′-GGGTGACAGGAGCCATC-3′.
The PCR primers for actinwere obtained from the LightCycler™-Primer
Set (Roche). Quantitative real-time PCRwas carried out in a LightCycler
(Roche) using LightCycler-FastStart DNA Master SYBR Green I (Roche).
Transfection of siRNA
Subconﬂuent cells cultured in a 48-well plate were transfected
twice at a 2- or 3-day interval with 30 nM of vimentin-speciﬁc, HPRT-
speciﬁc, or negative control (Invitrogen) siRNA duplexes using
Lipofectamine RNAiMAX (Invitrogen) following the manufacturer's
instructions. The siRNA target sequences were as follows: vimentin
(sense), 5′-ACCTTGAACGCAAAGTGGAATCTTT-3′; HPRT-S1 (sense), 5′-
AAGCCAGACUUUGUUGGAUUUGAAA-3′.Infection of Huh7 cells with HCV
Infectious HCV (JFH1 strain) particles were produced in Huh7.5.1
cells as described previously (Wakita et al., 2005). Culture supernatant
containing infectious HCV particles was collected and stored at −80 °C
until use. Subconﬂuent naïve Huh7, Huh7/hygro, or Huh7/vimentin
cells in 24-well or 48-well plates were exposed to normal culture
medium containing HCV particles (1.4–8 fmol core protein/well,
corresponding to moi=0.0175–0.1) for 6 h at 37 °C. Cells were then
washed and maintained in 500 μl (24-well) or 250 μl (48-well) of
normal culture medium for 6–7 days at 37 °C. To determine HCV
production activity, the amounts of HCV core protein in the culture
medium and cell lysates were quantiﬁed with an enzyme-linked
immunosorbent assay (ELISA) (Ortho® HCV antigen ELISA test, Ortho-
Clinical Diagnostics, Japan).
Assay for activity of HCV genomic RNA replication
The RNAs (30 μg) transcribed from pSGR-JFH1/Luc and pSGR-JFH1/
Luc-GND (Kato et al., 2005) were transfected into Huh7 cells (1.6×106
cells) by electroporation. Transfected cells in normal culture medium
were immediately seeded into 48-well plates at 9.0×104 cells/well.
Four hours after transfection, siRNAs were also transfected into these
cells. After incubation for 2.5 days, cells were harvested and the
luciferase activity in cell lysates was determined with the Luciferase
Assay System (Promega). Since the luciferase activities of the JFH1/Luc
replicon were ∼400-fold higher than those of the JFH1/Luc-GND
mutant replicon, background luciferase activity, which is independent
of replication activity, was very low in our experimental conditions.
Immunoﬂuorescence microscopy
Cells cultured on glass cover slips (in 24-well plates) were ﬁxed
in 1% formaldehyde-PBS for 1 h at 4 °C, permeabilized in PBS
containing 0.1% Triton X-100 for 5 min, and washed twice with PBS.
The cell monolayers were incubated with rabbit anti-vimentin
antibodies (1:100) and mouse anti-HCV core protein antibodies (1:
100) for 60 min at room temperature. After washing with PBS, the
cells were incubated with Alexa488-conjugated anti-mouse IgG,
Alexa594-conjugated anti-rabbit IgG, and DAPI (4′, 6′-diamidino-2-
phenylindole) (Invitrogen) for 60 min at 4 °C. Coverslips were
washed with PBS and mounted on glass slides. Immunoﬂuorescence
was visualized and quantitated with a confocal laser-scanning
microscope (Axiovert 100M, Carl Zeiss) equipped with a LSM510
system (Carl Zeiss).
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